Pancreatic Cancer Metastatic

Oncology·MeSH: Kidney Neoplasms

Prevalence

8.0 / 100K

Incidence

13.1 / 100K/yr

8 drugs in development·2 companies·13 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
Sintilimab injection	KYNTRA BIO INC. (KYNB)

Phase 2(6)

Drug	Company
FOLFIRI	Merus N.V. (MRUS)
Folfirinox	Merus N.V. (MRUS)
mFOLFIRINOX	Merus N.V. (MRUS)
mFOLFIRINOX	KYNTRA BIO INC. (KYNB)
mFOLFIRINOX infusion	Merus N.V. (MRUS)
mFOLFIRINOX Treatment Regimen	KYNTRA BIO INC. (KYNB)

Phase 1(1)

Drug	Company
individualized anti-tumor new antigen iNeo-Vac-R01 injection	KYNTRA BIO INC. (KYNB)

BioSniper tracks 8 drugs in development for Pancreatic Cancer Metastatic across 2 companies.

There are 13 clinical trials targeting Pancreatic Cancer Metastatic tracked by BioSniper.

The estimated prevalence of Pancreatic Cancer Metastatic is approximately 8.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.